Durable Response to Combined Dabrafenib and Trametinib in a Patient With BRAF K601E Mutation-Positive Lung Adenocarcinoma: A Case Report

JTO Clin Res Rep. 2021 Jul 3;2(8):100202. doi: 10.1016/j.jtocrr.2021.100202. eCollection 2021 Aug.

Abstract

Targeted therapy with combined dabrafenib and trametinib has been proven to provide clinical benefits in patients with NSCLC with a BRAF V600E mutation. Nevertheless, the treatment strategy for patients with NSCLC with BRAF non-V600E mutations remains limited. Here, we present a patient with NSCLC with a BRAF K601E mutation, a class II BRAF mutation, who had a durable response to targeted therapy with combined dabrafenib and trametinib.

Keywords: Adenocarcinoma; BRAF K601E mutation; Case report; Dabrafenib; Trametinib.

Publication types

  • Case Reports